Biotherapeutics News for July 2018

OBD presents latest data on the use of EpiSwitch™ in predicting patient response to immunotherapy and identifying lymphoma subtypes OBD presents latest data on the use of EpiSwitch™ in predicting patient response to immunotherapy and identifying lymphoma subtypes

EpiSwitch™ biomarkers have the potential to predict patient response to treatments with immune checkpoint inhibitors anti-PD-1 and anti-PD-L1 EpiSwitch™ biomarkers have been shown to offer prognostic stratifications in lymphoma patients Data presented at the ASH Summit on Emerging Immunotherapies for Hematologic Diseases on 13 July 2018, in Washington DC
21 July, 2018